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Abstract: The aim of this study was to evaluate the effect of palmitoylethanolamide (PEA),
a cannabimimetic compound and lipid messenger, on recovery from muscle damaging exercise.
Twenty-eight healthy young male participants attended the laboratory four times on subsequent
days. In the first visit, baseline characteristics were recorded before participants were randomized to
consume either liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin) or a matched placebo
(1 g maltodextrin) drink. Leg press exercise consisted of four sets at 80% of one repetition maximum
followed by a performance set. Muscle soreness, thigh circumference, blood lactate concentration,
biomarkers of muscle damage and inflammation, and transcription factor pathways were measured
pre- and immediately post-exercise and again at 1, 2, 3, 24, 48, and 72 h post-exercise. The leg press
exercise increased (p < 0.05) blood lactate concentration and induced muscle damage as evidenced by
increased muscle soreness, thigh circumference, biomarkers of muscle damage, and concentrations of
tumor necrosis factor-α. PEA reduced (p < 0.05) myoglobin and blood lactate concentrations and
increased protein kinase B phosphorylation following exercise. Taken together, these results indicate
PEA supplementation may aid in muscle recovery from repeat bouts of exercise performed within a
short duration by reducing myoglobin and lactate concentration.
Keywords: palmitoylethanolamide; recovery; leg press exercise; muscle damage; functional foods
1. Introduction
Exercise-induced muscle damage is a phenomenon caused by unaccustomed exercise that is
characterized by transient ultrastructural myofibrillar disruption [1,2]. Following exercise, there is
muscle soreness, decreased pressure pain threshold, localized swelling, and temporary reductions in
muscle strength, power, and range of motion in the affected limb [3]. The myofibrillar disruption is
accompanied by the systemic efflux of myocellular enzymes and proteins, including creatine kinase,
lactate dehydrogenase, and myoglobin. Exercise-induced muscle damage stimulates various cell
types within skeletal muscle to initiate subsequent tissue repair and remodeling including satellite,
inflammatory, vascular, and stromal cells that interact with each other within the extracellular
matrix [1,2].
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Exercise-induced muscle damage can limit recovery from a previous bout of exercise. Successful
recovery would enable an individual to return to training and competition quicker, and possibly allow
for higher exercise intensity to be performed [4]. Increasing the intensity and volume of training sessions
in a given period may allow for improved performance in subsequent competitions [4]. Non-steroidal
anti-inflammatory drugs are commonly prescribed to alleviate the symptoms of exercise-induced
muscle damage. However, there is evidence to suggest that long-term use of such drugs may impair
the skeletal muscle adaptive response to exercise and there are several reported side effects including
stomach issues [5]. Thus, there is a direct need for sustainable, long-term, treatments with fewer
potential side effects for the prevention and management of exercise-induced muscle damage [6].
Palmitoylethanolamide (PEA) is a cannabimimetic compound and lipid messenger found in a
wide variety of food sources that is hypothesized to reduce pain through endocannabinoid driven
activities or by reducing inflammation [7,8]. Several human studies investigated PEA as a treatment
for pain and a recent systematic review and meta-analysis, that identified 10 studies including data
from 786 participants who received PEA and 512 controls, demonstrated that PEA supplementation
was associated with significantly greater pain reduction compared to inactive control conditions [9].
The mechanisms responsible for the reduction in pain may be due to PEA agonism of peroxisome
proliferator activated receptor-α, which has been shown to have a major role in PEA mechanisms
for pain relief [10]. PEA also has an essential role in the suppression of inflammation by reducing
the activity of pro-inflammatory enzymes cyclooxygenase, endothelial nitric oxide synthase and
inducible nitric oxide synthases [11], and mast cell activation [12,13]. These mechanisms of action
may also reduce painful symptoms that result from exercise-induced muscle damage and would be
advantageous for individuals who require rapid recovery between acute successive bouts of exercise
(e.g., sports tournament) [14]. However, to our knowledge no research has undertaken this.
Accordingly, the aim of this study is to evaluate the effects of PEA on recovery from
muscle-damaging exercise. We hypothesize that PEA supplementation immediately before and
after exercise will reduce pain and decrease localized swelling through a reduction in pro-inflammatory
intramuscular enzymes and cytokines. Additionally, based on the mechanisms of action of PEA on
inflammation we hypothesize that PEA will also reduce muscle damage because of the inflammatory
processes involved in muscle injury and repair.
2. Materials and Methods
2.1. Participants
Twenty-eight healthy young male participants with prior experience in resistance exercise training
participated in the study and provided written informed consent prior to testing (Table 1). The exclusion
criteria included any unstable or serious illness, use of long-term medications, malignancy or treatment
for malignancy within the previous two years, tobacco use, medically prescribed diet, slimming diet,
vegan diet, macrobiotic diet, chronic past or current alcohol abuse, allergy to any study ingredients,
serious mood disorders, insomnia, night-shift employment, any diagnosed neurological conditions,
recent musculoskeletal injuries, and participation in any other clinical trial in the past three months.
The inclusion criteria included normal dietary habits, body mass index between 18.5 to 35 kg/m2,
recreationally trained and achieving at least 150 min of exercise per week, and at least six months of
resistance training experience in the past year. Experimental procedures were approved by the Bellberry
Human Research Ethics Committee (HREC 2017-11-841), conformed to the Declaration of Helsinki and
registered with the Australia and New Zealand Clinical Trials Registry (ANZCTRN1261800285257).
2.2. Experimental Design
A randomized, double-blind, placebo-controlled design was employed for this study. Participants
attended the laboratory four times on subsequent days between 6–8 am (Figure 1). During the first visit,
height, body mass, waist, hip and thigh circumference, resting brachial blood pressure, and heart rate
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(HEM-7121, Omron Healthcare Co., Kyoto, Japan) were measured. Participants were then familiarized
with all testing procedures and randomized to consume either liquid PEA or a matched placebo drink
pre- and post-exercise. Exercise consisted of four leg press sets at 80% of one repetition maximum
(1-RM) and one performance set at 70% 1-RM. Muscle soreness, thigh circumference, blood lactate
concentration, biomarkers of muscle damage and inflammation, and transcription factor pathways were
measured pre- and immediately post-exercise and then again at 1, 2, 3, 24, 48, and 72 h post-exercise.
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2.3. Treatments
The PEA group consumed 167.5 mg of Levagen+ (150 mg of PEA and 17.5 mg of excipients) with
832.5 mg of malt dextrin and the placebo group consumed 1 g of malto extrin. Levagen+ contains
palmitoylethanolamide, coconut oil (fractionated), polyglycerol polyricinoleate, citrus oil, olive oil,
lecithin, dl-alpha tocopheryl acetate, and silicon dioxide. Previous resea ch showed a two-fold increase
in plasma concentrations of PEA after oral administration of 300 mg [15]. E ch treatment was mixe
with 250 mL of water in a opaque bottle. To adhere to the double-blind protocol, a third party not
associated with the study created the pre-mixed drinks. Each treatment was provide at the following
time points: pre-exercise, post-exercise, 3 h post-ex rcise, 24 h po t-exercis , and 48 h post-exercise
(Figure 1).
2.4. Determination of One Repetition Maximum Load
Thirty minutes after the consumption of the treatments, participants completed a 5 min warm-up
at a self-selected pace on a cycle ergo eter (Ergomedic 828 E, Monark, Vansbro, Sweden). Particip nts
then stretched major mus l groups of th lower limbs followed by 10 repetitions of a leg press ex rcise
(45 Degree Leg Press, Force USA, Draper, UT, USA) at 50% of esti ated 1-RM followed by 2 min rest.
The weight on the leg press was then increased to approximately 70% of the estimated 1-RM and
participants completed 4 to 6 repetitions followed by 2 min rest. Weight was added onto the leg press
to approximately 90% of estimated 1-RM and participants completed one repetition followed by 2 min
rest. Weight was then increased to 100% of estimated 1-RM and participants attempted to complete
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a repetition. Participants were given up to 7 attempts to achieve 1-RM and were allowed to rest for
3 min in-between attempts. Once 1-RM testing was complete participants rested for 5 min.
2.5. Leg Press Exercise
Participants completed four sets of a leg press exercise at 80% of 1-RM. For each set, the participant
was asked to perform as many repetitions as possible, until volitional exhaustion. Each repetition was
completed as fast as possible with maximal intent. The participants rested for 60 s between each set.
Each repetition was recorded using an accelerometer-based system attached to the leg press sled to
determine repetition velocity and power (Push Band 2.0, Push Inc, Toronto, Canada). Once the fourth
set was complete, participants rested for 5 min and were then taken through testing for their 1-RM
again. At 2 h and 45 min after the second 1-RM test the participants performed a third 1-RM test after
a 5 min self-selected pace cycling warm-up. After a 5 min rest period, the participants performed one
set of leg press exercises at 70% of 1-RM achieved at baseline. The participants were instructed to
complete as many repetitions as possible with maximal leg speed. A 5 min cycling warm-down was
then completed at a self-selected pace.
2.6. Muscle Soreness, Thigh Circumference, and Blood Lactate Concentration
Muscle soreness was measured using a visual analog scale which consisted of a 10 cm line with
end points labeled “no pain” (left) and “unbearable pain” (right). Thigh circumference was measured at
the point equidistant from trochanterion and tibiale laterale in a relaxed standing position. A fingertip
capillary blood sample was used to measure blood lactate concentration (The Edge Lactate Analyzer,
Apex Biotechnology Corporation, Hsinchu City, Taiwan).
2.7. Biomarkers of Muscle Damage and Inflammation and Phosphoprotein Signaling Pathways
Blood was collected into ethylenediaminetetraacetic acid plasma and serum vacutainers (BD,
Plymouth, UK). Plasma samples were immediately centrifuged, whilst serum samples were incubated
at room temperature for 30 min before centrifugation at 1500× g for 10 min at 4 ◦C. Separated plasma and
serum were aliquoted and stored at −80 ◦C until biochemical assays were performed. Serum creatine
kinase, lactate dehydrogenase, myoglobin, and high sensitivity C-reactive protein were analyzed in
duplicate using a clinical chemistry analyzer (BK400, Biobase, Jinan, China).
Mononuclear cells were collected using cell preparation tubes (CPT) (BD, Plymouth, UK). Briefly,
whole blood collected in the CPTs was immediately centrifuged at 1500× g for 20 min at room
temperature. Half of the separated plasma was aspirated and discarded whilst the remaining plasma
and cell layer were transferred to a 15 mL conical centrifuge tube using a Pasteur pipette. Phosphate
buffered saline (PBS) was added to the conical tube and the tube was inverted 5 times to wash the
cell layer. The cell/PBS mix was centrifuged at 300 relative centrifugal force (RCF) for 15 min at room
temperature. After removing the supernatant, the washing step was repeated with 10 mL of PBS.
The remaining cell layer was resuspended after aspiration in PBS with a protease inhibitor cocktail
(Sigma-Aldrich, Milwaukee, WI, USA) and stored at −80 ◦C until biochemical assays were performed.
Mononuclear cells were analyzed for protein kinase B, cAMP response element-binding
protein, extracellular signal-regulated kinases 1/2, c-Jun N-terminal kinases, nuclear factor
kappa-light-chain-enhancer of activated B cells, p38 mitogen-activated protein kinases, ribosomal
protein S6 kinase beta-1, and signal transducer and activator of transcription 3 and 5 using a
multi-pathway 9-plex magnetic bead kit (cat. # 48-680MAG, Merck, Darmstadt, Germany). Each well
had a known amount of cell protein added to ensure all results were relative. Serum interleukin-10
and 6, and tumor necrosis factor-α were analyzed in duplicate (Luminex 200, Austin, TX, USA) with
high sensitivity Milliplex kits and calibrators (Merck Millipore, Darmstadt, Germany).
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2.8. Data Analyses
Statistical analyses were performed using IBM SPSS Statistics (version 25.0) for Windows
(IBM, Chicago, IL, USA). A sample size of 14 per group was calculated based on the power to
detect a change of 20% in creatine kinase (300 IU/L down to 240 IU/L); effect size: 0.857, alpha error
prob: 0.05, power 0.8. This allowed for a 20% drop out. All data were confirmed as parametric
via a Shapiro–Wilk test for normality. Baseline participant characteristics between groups were
analyzed with an independent samples t-test. A two-way ANOVA was used to analyze the effects
of “time” (sets 1–4 and performance set for exercise and pre-, immediately post-exercise, and 1, 2,
3, 24, 48, and 72 h post-exercise for all other measures) and “treatment” (PEA vs. placebo) with a
Greenhouse–Geisser correction where appropriate. Where significant treatment baseline differences
were apparent (interleukin-6, cAMP response element-binding protein), results were normalized to
baseline values prior to subsequent statistical analysis. Significant between-treatment differences were
further explored using one-way repeated-measures ANOVA. Planned pairwise comparisons were
made with repeated measures t-tests and the Bonferroni post-hoc adjustment. Statistical significance
was set at p < 0.05. Data are presented as mean ± SD.
3. Results
There were no between-group differences in baseline participant characteristics (Table 1), indicating
that the groups were well matched prior to testing. No adverse effects of the treatments were reported
by the participants throughout the trial.
Table 1. Baseline participant characteristics for palmitoylethanolamide (PEA) and placebo groups.
Values are mean ± SD.
PEA Placebo
Age (years) 27 ± 4 26 ± 4
Height (m) 1.79 ± 0.10 1.80 ± 0.10
Weight (kg) 84 ± 12 83 ± 15
Body mass index (kg/m2) 25 ± 2.6 26 ± 2.8
Systolic blood pressure (mmHg) 123 ± 9 124 ± 10
Diastolic blood pressure (mmHg) 76 ± 4 75 ± 11
Waist circumference (cm) 87 ± 7 87 ± 9
Hip circumference (cm) 102 ± 7 102 ± 7
Waist to hip ratio 0.86 ± 0.04 0.85 ± 0.05
3.1. Leg Press Exercise
Mean power (Figure 2) performed during leg press exercise in both PEA and placebo groups
decreased (p < 0.01) during sets 1–4, but there were no main effects of treatment or time by treatment
interactions. There were also no between-group differences for the performance set.
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Table 2. Phosphoprotein signaling pathways for PEA and placebo groups. Values are mean ± SD, # p < 0.05 compared with pre-exercise.
Pre-exercise Post-exercise +1 h +2 h +3 h +24 h +48 h +72 h
PKB (MFI) PEA 4682 ± 2933 9362 ± 4185# 6146 ± 4147 5355 ± 3694 5972 ± 3313 6263 ± 4015 6163 ± 3667 4461 ± 3772
Placebo 4444 ± 1749 4996 ± 4642 5405 ± 2574 4911 ± 2625 4798 ± 2634 4832 ± 2515 4494 ± 2053 5298 ± 2226
CREB (MFI) PEA 98.5 ± 43.7 88.4 ± 61.7 92.7 ± 63.3 87.3 ± 51.0 122 ± 123 115 ± 105 73.0 ± 28.1 165 ± 222
Placebo 66.4 ± 29.7 58.3 ± 27.5 94.8 ± 99.6 65.7 ± 20.7 74.5 ± 24.6 68.4 ± 38.3 62.1 ± 22.1 66.8 ± 29.6
ERK 1/2 (MFI) PEA 39.6 ± 13.7 37.9 ± 15.8 40.3 ± 14.0 43.6 ± 13.7 40.9 ± 12.2 43.3 ± 15.0 40.2 ± 16.7 42.9 ± 13.0
Placebo 38.2 ± 12.1 41.5 ± 13.2 44.5 ± 14.6 44.0 ± 13.8 42.0 ± 12.1 40.5 ± 12.7 41.9 ± 14.7 38.9 ± 14.9
JNK (MFI) PEA 115 ± 92 106 ± 102 135 ± 101 120 ± 140 162 ± 133 105 ± 120 117 ± 119 120 ± 97
Placebo 103 ± 98 78 ± 64 138 ± 114 107 ± 93 126 ± 107 101 ± 93 87 ± 70 99 ± 93
NF-κB (MFI) PEA 17.9 ± 4.1 21.6 ± 8.1 17.8 ± 5.6 19.5 ± 9.1 21.0 ± 11.4 23.9 ± 17.9 17.1 ± 4.5 19.0 ± 7.2
Placebo 16.4 ± 5.7 18.0 ± 5.6 20.4 ± 7.0 17.4 ± 4.1 20.3 ± 7.1 19.0 ± 4.9 20.9 ±4.1 22.3 ± 8.5
p38MAPK (MFI) PEA 6188 ± 1791 6762 ± 1245 6184 ± 1545 5605 ± 2759 6879 ± 1706 6790 ± 2830 5772 ± 2896 5283 ± 2705
Placebo 5926 ± 2047 6080 ± 1933 6415 ± 1698 6504 ± 1923 6556 ± 1455 6448 ± 2629 6782 ± 2061 5643 ± 2524
RPS6KB1 (MFI) PEA 68.3 ± 70.9 47.5 ± 26.6 46.5 ± 22.6 49.6 ± 34.1 51.0 ± 31.3 42.6 ± 12.0 49.4 ± 36.4 55.5 ± 23.3
Placebo 39.7 ± 13.0 30.3 ± 11.8 45.0 ± 29.0 37.7 ± 10.2 38.1 ± 11.1 32.9 ± 15.2 46.0 ± 42.9 44.1 ± 17.5
STAT3 (MFI) PEA 51.9 ± 26.8 49.7 ± 19.8 55.6 ± 26.5 48.9 ± 22.7 48.6 ± 19.3 51.1 ± 19.3 43.4 ± 15.5 52.4 ± 27.0
Placebo 42.5 ± 18.3 42.0 ± 16.2 44.0 ± 24.6 46.2 ± 24.0 48.4 ± 28.9 45.5 ± 26.5 43.2 ± 26.0 47.4 ± 19.9
STAT5 (MFI) PEA 47.2 ± 32.4 46.3 ± 18.9 48.8 ± 20.7 50.8 ± 30.5 53.4 ± 25.9 42.8 ± 14.6 45.6 ± 22.8 41.1 ± 11.9
Placebo 38.5 ±10.1 40.4 ± 12.4 37.7 ± 6.5 39.3 ± 13.4 39.9 ±9.9 38.3 ± 6.5 40.6 ± 9.4 38.9 ± 12.3
Abbreviations: MFI, mean fluorescence intensity; PKB, protein kinase B; CREB, cAMP response element-binding protein; ERK 1/2, extracellular signal–regulated kinases 1/2; JNK, c-Jun
N-terminal kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; p38MAPK, p38 mitogen-activated protein kinases; RPS6KB1, ribosomal protein S6 kinase beta-1;
STAT, signal transducer and activator of transcription.
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3.3. Biomarkers of Muscle Damage
Myoglobin concentration peaked +1 h after exercise and declined thereafter (p < 0.01; Figure 5).
Myoglobin concentration was lower for the PEA than placebo group at +1, +2, and +3 h post exe cise
(p < 0.05). Creatine kinase peaked +24 h after exercise and decreased thereafter (p < 0.05). Th re was
no change in lactat dehydrogenase over time. There were also no main eff cts of treatment or time by
treatment inter tions for creatine kinas and lactate dehydrogenase (Tabl 3).
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Table 3. Thigh circumference and biomarkers of muscle damage and inflammation for palmitoylethanolamide (PEA) and placebo groups. Values are mean ± SD.
Pre-exercise Post-exercise +1 h +2 h +3 h +24 h +48 h +72 h
Thigh
Circumference (cm)
PEA 57.3 ± 3.93 58.5 ± 3.72 57.6 ± 3.78 57.6 ± 3.69 57.7 ± 3.71 57.5 ± 3.83 56.9 ± 3.82 57.5 ± 3.81
Placebo 56.2 ± 4.81 57.4 ± 5.08 56.4 ± 4.60 56.3 ± 4.78 56.5 ± 4.92 56.5 ± 4.51 56.7 ± 4.40 56.6 ± 4.85
Creatine
Kinase (IU/L)
PEA 213 ± 119 228 ± 130 256 ± 223 257 ± 213 261 ± 210 310 ± 220 298 ± 233 233 ± 225
Placebo 180 ± 91 204 ± 106 196 ± 101 204 ± 97 232 ± 107 261 ± 100 226 ± 88 211 ± 138
Lactate
Dehydrogenase (IU/L)
PEA 217 ± 99 183 ± 42 193 ± 44 204 ± 48 176 ± 54 164 ± 55 170 ± 27 197 ± 51
Placebo 182 ± 30 211 ± 44 184 ± 61 202 ± 86 201 ± 84 162 ± 24 178 ± 31 173 ± 22
HS C-reactive
Protein (mg/L)
PEA 1.52 ± 2.12 1.60 ± 2.16 1.39 ± 1.88 1.49 ± 2.07 1.36 ± 1.83 1.24 ± 1.49 1.41 ± 1.49 1.09 ± 1.45
Placebo 1.26 ± 0.85 1.28 ± 0.87 1.17 ± 0.81 1.14 ± 0.79 1.15 ± 0.78 1.17 ± 1.04 1.17 ± 0.84 1.20 ± 0.95
Interleukin-10 (pg/mL) PEA 12.1 ± 10.1 20.1 ± 31.6 17.0 ± 17.2 15.9 ± 17.4 15.9 ± 16.8 13.5 ± 10.7 14.4 ± 12.0 12.2 ± 11.6
Placebo 16.8 ± 22.0 17.5 ± 24.0 16.0 ± 21.8 15.4 ± 17.2 14.4 ± 17.6 11.6 ± 11.1 12.5 ± 11.6 12.6 ± 10.0
Interleukin-6 (pg/mL) PEA 12.0 ± 9.43 12.2 ± 9.12 10.4 ± 7.23 11.6 ± 8.09 11.7 ± 7.56 11.4 ± 7.17 10.8 ± 7.01 10.6 ± 7.52
Placebo 6.23 ± 4.93 6.59 ± 4.29 5.13 ± 3.69 5.44 ± 3.71 5.92 ± 3.79 5.54 ± 3.86 5.50 ± 3.73 5.20 ± 3.38
Tumor necrosis
factor-α (pg/mL)
PEA 8.03 ± 5.51 9.17 ± 7.22 7.25 ± 4.48 7.69 ± 4.61 7.45 ± 3.40 8.38 ± 4.13 7.16 ± 3.53 7.41 ± 3.51
Placebo 8.58 ± 3.72 9.36 ± 3.11 7.80 ± 2.41 7.76 ± 3.50 7.97 ± 3.14 8.07 ± 2.57 7.52 ± 1.88 7.75 ± 2.34
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3.4. Biomarkers of Inflammation
There were no main effects of time or treatment for interleukin-6 and 10 (Table 3), demonstrating
that these inflammatory markers were not changed by the exercise. Tumor necrosis factor-α peaked
post exercise and declined thereafter (p < 0.05), but there were no main effects of treatment or time by
treatment interactions (Table 3).
3.5. Phosphoprotein Signaling Pathways
Protein kinase B phosphorylation peaked immediately after exercise for the PEA group only
(p < 0.05; Table 2) and returned to baseline values 1 h after exercise. There were no main effects
of time or treatment for: cAMP response element-binding protein, extracellular signal-regulated
kinases 1/2, c-Jun N-terminal kinases, nuclear factor kappa-light-chain-enhancer of activated B cells,
p38 mitogen-activated protein kinases, ribosomal protein S6 kinase beta-1, and signal transducer
and activator of transcription 3 and 5 (Table 2), demonstrating that these phosphoprotein signaling
pathways were not induced by the exercise.
4. Discussion
To our knowledge, this is the first study to examine the effects of PEA supplementation on recovery
from muscle damaging exercise. In contrast to our hypothesis, we observed that PEA supplementation
immediately before and after exercise did not reduce pain and localized swelling through a reduction
in pro-inflammatory intramuscular enzymes and cytokines; although there was a significant reduction
in blood lactate and myoglobin concentrations following PEA supplementation. PEA supplementation
also increased protein kinase B phosphorylation immediately post exercise.
4.1. Leg Press Exercise
The leg press exercise increased blood lactate concentration in both the PEA and placebo groups,
peaking at 7.38 ± 3.09 and 8.81 ± 2.44 mmol/L, respectively. This demonstrated that the exercise was at
a high intensity and increased glycolytic metabolism [16], which is similar to other reported values [17].
The exercise bout also induced muscle damage, evidenced by the increased subjective rating of
muscle soreness, thigh circumference, and biomarkers (myoglobin and creatine kinase), which are all
commonly found to increase after muscle damaging exercise [1,2]. The inflammatory biomarker tumor
necrosis factor-α also increased following exercise, which is similar to some [18], but not all [19,20]
previous studies that investigated resistance-based exercise.
There was no change in the other biomarkers of muscle damage (lactate dehydrogenase) or
inflammation (high sensitivity C-reactive protein and interleukin-10 and 6) following the leg press
exercise. The responses of lactate dehydrogenase [21,22], C-reactive protein [23], and interleukin-10 [24]
to resistance exercise are variable. Interleukin-6 usually increases after resistance exercise, but it may be
that the volume of the leg press exercise was too little to see any changes in this biomarker [23]. Lastly,
other than protein kinase B phosphorylation, there were no changes in any other phosphoprotein
signaling pathways measured after exercise. This may be that the stress of the exercise was not great
enough to induce these signal transduction pathways [25,26].
4.2. Effects of PEA Supplementation
We hypothesized that PEA supplementation immediately before and after exercise would reduce
pain and localized swelling through a reduction in pro-inflammatory intramuscular enzymes and
cytokines. Our hypothesis was based on evidence from several human studies that investigated PEA
as a treatment for pain and a recent systematic review and meta-analysis, that identified 10 studies
including data from 786 participants who received PEA and 512 controls, demonstrated that PEA
supplementation was associated with significantly greater pain reduction compared to inactive control
conditions [9]. The mechanisms responsible for the reduction in pain may be due to PEA agonism
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of peroxisome proliferator activated receptor-α, which was shown to have a major role in the PEA
mechanisms for pain relief [10]. PEA also has an essential role in the suppression of inflammation by
reducing the activity of the pro-inflammatory enzyme’s cyclooxygenase and endothelial and inducible
nitric oxide synthases [11], and by reducing mast cell activation [12,13]. The mechanisms responsible
for this anti-inflammatory effect were investigated more recently. PEA inhibits phosphorylation
of kinases involved in activation of pro-inflammatory pathways, such as c-Jun N-terminal kinase
and extracellular signal-regulated kinases, and the nuclear translocation of the transcription factors
kappa-light-chain-enhancer of activated B cells [27,28]. However, we did not see a reduction in
markers of inflammation or evidence of the upregulation in phosphoprotein signaling pathways.
The reason we did not observe a reduction in inflammation may be due to several reasons. Firstly,
our supplementation protocol was acute and not chronic as undertaken in previous studies [12,13,29].
Secondly, we measured systemic rather than localized inflammation impacting the resolution of
inflammation measured. Finally, the volume of exercise may have been insufficient to elevate all
inflammatory markers, and therefore any intervention would be unable to reduce these.
PEA was provided in an acute context to investigate its short-term effects on muscle
recovery. As inflammation is needed for long-term muscle growth and PEA supposedly acts in
an anti-inflammatory mechanism, then chronic administration would possibly provide a negative
stimulus for chronic exercise adaptation.
We observed myoglobin to be lower for the PEA group (p < 0.05; Figure 5) compared to the placebo.
Myoglobin is one of the most commonly used markers of skeletal muscle damage and represents
a proxy marker of damage to the muscle cell membrane [30]. When muscle is damaged, as with
resistance exercise, myoglobin leaks into the circulation due to muscle cell disruption and, therefore,
circulating concentrations of myoglobin are frequently used as markers of exercise-induced muscle
damage [30]. There are several possible explanations for the discovery that PEA may reduce myoglobin
concentration. Firstly, the reduction in myoglobin concentration might represent a decrease in muscle
damage resulting from modification of cytokine synthesis in response to PEA. However, we think
this is unlikely since, there were no changes to the cytokines measured after PEA supplementation
compared to the placebo. Secondly, PEA may reduce muscle protein breakdown, possibly due to an
enhanced insulin response and muscle protein turnover. Finally, another possible explanation is that
PEA supplementation promotes the clearance of myoglobin from circulation.
There are conflicting results in previous research on the relationship between muscle damaging
exercise, myoglobin, and other markers of muscle damage. One study by Isaacs et al. describes
that only “high responders”, those whose creatine kinase (CK)increased above 1000 U/L after muscle
damaging exercise, had a corresponding increase in Mb. It was also noted that only “high responders”
also increased C-reactive protein (CRP) [31]. However, those that were “low responders” did not have
a corresponding increase in CK or CRP suggesting that changes in Mb, CK, and CRP have a non-linear
relationship. This could be why we observed a reduction in Mb but no changes in CK or CRP. We are
unsure as to the mechanism between PEA and the reduction in Mb, but no congruent reduction in
other markers of muscle damage was found.
Peak blood lactate concentration was lower following PEA supplementation compared to the
placebo. A lower blood lactate concentration correlates with increased aerobic energy metabolism and
decreased anaerobic energy metabolism. This could be due to either a decreased lactate net production
or an increased net lactate uptake into surrounding tissues. It is unknown what the mechanism is
for reduced lactate concentration post-exercise in the PEA group. Supplementation with PEA might
therefore allow exercise to be maintained at a higher intensity for longer. It could be suggested that
consumption of PEA may allow for higher exercise intensities to be achieved after an initial exercise
session. This would allow for an improved training response or sports performance, particularly for
those who exercise or compete within quick succession (within a few hours).
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5. Conclusions
To our knowledge, this is the first study to examine the effects of PEA supplementation on recovery
from muscle-damaging exercise. In contrast to our hypothesis, we observed that PEA supplementation
immediately before and after leg press exercise did not reduce pain and localized swelling through
a reduction in pro-inflammatory intramuscular enzymes and cytokines. This may be because of the
volume of the exercise and/or the acute supplementation protocol used. PEA was however able to
reduce myoglobin and increase protein kinase B phosphorylation following exercise. Taken together,
these results may indicate that PEA supplementation is able to aid in muscle recovery from repeat
bouts of exercise performed within 3 h.
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